Products - Chronic liver disease | Topic | NICE

Showing 7 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Seladelpar for previously treated primary biliary cholangitis [ID6429]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
20 August 2025
Expected publication date:
5 November 2025
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Ex-situ machine perfusion devices for liver transplants
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
TBC